share_log

Short Interest in Inozyme Pharma, Inc. (NASDAQ:INZY) Decreases By 18.8%

Short Interest in Inozyme Pharma, Inc. (NASDAQ:INZY) Decreases By 18.8%

空头股数在Inozyme制药公司(纳斯达克代码：INZY)的跌幅为18.8%
kopsource ·  2022/08/31 17:13

Inozyme Pharma, Inc. (NASDAQ:INZY – Get Rating) was the target of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 267,000 shares, a decrease of 18.8% from the July 31st total of 328,800 shares. Approximately 1.2% of the company's shares are short sold. Based on an average daily volume of 180,100 shares, the short-interest ratio is presently 1.5 days.

Inozyme Pharma，Inc.(纳斯达克：Inzy-Get评级)是空头股数8月份大幅下跌的目标。截至8月15日，空头股数共有267,000股，较7月31日的328,800股减少18.8%。该公司约1.2%的股票被卖空。以日均成交量180,100股计算，目前短息比率为1.5天。

Inozyme Pharma Stock Down 0.7 %

Inozyme Pharma股价下跌0.7%

Shares of NASDAQ:INZY traded down $0.02 on Wednesday, hitting $3.03. 1,072 shares of the company traded hands, compared to its average volume of 70,788. The stock has a 50 day simple moving average of $4.11 and a 200-day simple moving average of $4.43. The company has a market cap of $121.65 million, a PE ratio of -1.21 and a beta of 0.09. Inozyme Pharma has a 52 week low of $3.01 and a 52 week high of $17.55.

周三，纳斯达克的股价下跌了0.02美元，跌至3.03美元。该公司1,072股易手，而其平均成交量为70,788股。该股的50日简单移动均线切入位为4.11美元，200日简单移动均线切入位为4.43美元。该公司市值为1.2165亿美元，市盈率为-1.21，贝塔系数为0.09。Inozyme Pharma的52周低点为3.01美元，52周高点为17.55美元。

Get
到达
Inozyme Pharma
Inozyme制药公司
alerts:
警报：

Analyst Upgrades and Downgrades

分析师升级和下调评级

Several analysts have commented on INZY shares. Wedbush lowered their price objective on shares of Inozyme Pharma from $25.00 to $23.00 and set an "outperform" rating for the company in a report on Tuesday, May 10th. Jefferies Financial Group assumed coverage on shares of Inozyme Pharma in a report on Thursday, May 26th. They set a "hold" rating and a $5.00 target price on the stock.

几位分析师对Inzy的股票发表了评论。韦德布什在5月10日(周二)的一份报告中将Inozyme Pharma的股票目标价从25.00美元下调至23.00美元，并为该公司设定了“跑赢大盘”的评级。杰富瑞金融集团在5月26日星期四的一份报告中对Inozyme Pharma的股票进行了报道。他们为该股设定了“持有”评级和5.00美元的目标价。

Hedge Funds Weigh In On Inozyme Pharma

对冲基金参与Inozyme Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of INZY. Adage Capital Partners GP L.L.C. lifted its position in Inozyme Pharma by 8.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,599,028 shares of the company's stock valued at $10,905,000 after purchasing an additional 131,200 shares in the last quarter. Northern Trust Corp raised its holdings in Inozyme Pharma by 4.0% during the fourth quarter. Northern Trust Corp now owns 120,762 shares of the company's stock valued at $823,000 after acquiring an additional 4,661 shares during the period. Suvretta Capital Management LLC lifted its position in shares of Inozyme Pharma by 2.7% in the fourth quarter. Suvretta Capital Management LLC now owns 1,013,216 shares of the company's stock valued at $6,910,000 after acquiring an additional 26,816 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Inozyme Pharma during the second quarter worth about $53,000. Finally, Citigroup Inc. raised its stake in Inozyme Pharma by 241.6% during the 1st quarter. Citigroup Inc. now owns 12,517 shares of the company's stock valued at $51,000 after purchasing an additional 8,853 shares during the period.
几家对冲基金和其他机构投资者最近买卖了Inzy的股票。Adage Capital Partners GP L.L.C.在第四季度将其在Inozyme Pharma的头寸提高了8.9%。Adage Capital Partners GP L.L.C.在上个季度额外购买了131,200股后，现在拥有1,599,028股该公司的股票，价值10,905,000美元。北方信托公司在第四季度将其在Inozyme Pharma的持股增加了4.0%。北方信托公司目前拥有120,762股该公司股票，价值823,000美元，在此期间又购买了4,661股。Suvretta Capital Management LLC在第四季度将其在Inozyme Pharma的股票头寸提高了2.7%。Suvretta Capital Management LLC在上个季度增持了26,816股后，现在拥有1,013,216股该公司股票，价值6910,000美元。Virtu Financial LLC在第二季度购买了Inozyme Pharma的新股，价值约53,000美元。最后，花旗集团在第一季度将其在Inozyme Pharma的持股比例提高了241.6%。花旗集团目前持有该公司12,517股股票，价值51,000美元，在此期间又购买了8,853股。

About Inozyme Pharma

关于Inozyme Pharma

(Get Rating)

(获取评级)

Inozyme Pharma, Inc, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis.

Inozyme Pharma，Inc.是一家罕见疾病生物制药公司，致力于开发治疗影响血管系统、软组织和骨骼疾病的异常矿化的疗法。该公司的主要候选产品是INZ-701，这是一种可溶的重组蛋白，用于治疗ENPP1和ABCC6缺乏症等罕见的遗传性疾病，以及治疗钙质缺乏症。

Featured Stories

专题报道

  • Get a free copy of the StockNews.com research report on Inozyme Pharma (INZY)
  • Crowdstrike Stock Retraces, As Earnings Sober Expectations
  • Will The Institutions Buy The Dip In Ambarella Stock?
  • PVH Corporation Is On Track For Capital Returns
  • Can Pinterest Rally On Support From Big Investor With Conviction?
  • Chargepoint Rallies, Despite Weaker Earnings
  • 免费获取StockNews.com关于Inozyme Pharma的研究报告(Inzy)
  • CrowdStrike股价回落，盈利超出预期
  • 这些机构会在安巴雷拉入股抄底吗？
  • PVH公司有望实现资本回报
  • Pinterest能否坚定地获得大投资者的支持？
  • ChargePoint上涨，尽管收益疲软

Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

接受Inozyme Pharma Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Inozyme Pharma和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发